MAPT and Alzheimer disease: Our ability to detect seeding activity in 10−7–10−10 dilutions of AD brains suggests that our minimal detectable concentration of AD-associated tau seeds (which must be a subset of total tau) in a test sample should be ≤ 1–1000 fM (based on monomer concentration) or 0.05–50 fg per 1 μL test sample.